Current Report Filing (8-k)
January 05 2022 - 06:05AM
Edgar (US Regulatory)
0001476963 false 0001476963 2022-01-04
2022-01-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (date of earliest event reported):
January 4, 2022
Heat Biologics, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
001-35994 |
26-2844103 |
(Commission File
Number) |
(IRS Employer Identification
No.) |
627 Davis Drive,
Suite 400
Morrisville,
North Carolina
27560
(Address of principal executive offices and zip code)
(919)
240-7133
(Registrant’s telephone number including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule
14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
Common Stock, $0.0002 par value per share |
HTBX |
The Nasdaq Stock Market
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨ |
|
If an emerging growth company, indicate by checkmark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item
7.01. Regulation FD Disclosure.
Heat Biologics, inc. (the “Company”) will be
making several presentations to
investors over the next
several weeks. In connection with the presentations, the
Company intends to discuss the investor presentation, which is
furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in this Item 7.01 and in the investor
presentation attached as Exhibit 99.1 to this Current Report on
Form 8-K shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information
contained in this Item 7.01 and in the investor presentation
attached as Exhibit 99.1 to this Current Report on Form 8-K shall
not be incorporated by reference into any filing with the U.S.
Securities and Exchange Commission made by the Company, whether
made before or after the date hereof, regardless of any general
incorporation language in such filing.
The investor presentation
attached as Exhibit 99.1 to this Current Report on Form 8-K
includes “safe harbor” language pursuant to the Private Securities
Litigation Reform Act of 1995, as amended, indicating that certain
statements contained therein are “forward-looking” rather than
historical.
The Company undertakes no
duty or obligation to update or revise the information contained in
this Current Report on Form 8-K, although it may do so from
time to time if its management believes it is appropriate. Any such
updating may be made through the filing of other reports or
documents with the Securities and Exchange Commission, through
press releases or through other public disclosures.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 is furnished with this
Current Report on Form 8-K:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Dated: January 5, 2022 |
HEAT BIOLOGICS, INC. |
|
|
|
|
|
|
By: |
/s/ Jeffrey Wolf |
|
Name: |
Jeffrey Wolf |
|
Title: |
Chairman, President and
Chief Executive Officer |
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Jan 2023 to Feb 2023
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Feb 2022 to Feb 2023